Drug Shortage Prevention Act of 2023

This bill requires drug manufacturers to notify the FDA (Secretary) about potential shortages of critical drugs - defined as life-saving, life-sustaining, or essential for treating debilitating conditions - up to six months in advance for planned disruptions, or within 10 business days for sudden issues like supply chain problems or increased demand. Notifications must include reasons for shortages, expected duration, alternative ingredient sources, and details about related medical devices. Manufacturers must also submit annual reports (in March and September) detailing their supply chains, including supplier names and drug production quantities for critical ingredients. The bill directly affects manufacturers of these "covered drugs" by mandating transparent reporting to prevent shortages.